巴拿马库纳美洲印第安人中异喹胍代谢率的单峰分布。
Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama.
作者信息
Jorge L F, Arias T D, Inaba T, Jackson P R
机构信息
College of Pharmacy, University of Panamá.
出版信息
Br J Clin Pharmacol. 1990 Aug;30(2):281-5. doi: 10.1111/j.1365-2125.1990.tb03776.x.
Abstract
- The metabolic oxidation of debrisoquine (DB) was studied in 89 non-related Cuna Amerindian subjects. 2. Means and standard deviations for urinary recoveries of the intact drug and its 4-hydroxy metabolite (4-HD) were: %DB: 6.8 +/- 4.5; %4-HD: 16.0 +/- 9.1; %sum: 22.8 +/- 12.0. The log10 metabolic ratios for DB (LMRDB) were distributed within a single mode of insignificant skewness (-0.01, P greater than 0.10), which was unimodal (log kernel density and maximum likelihood methods) and normal (chi 2 = 22.5; d.f. = 15; P greater than 0.09; power of the test greater than 80%). 3. Therefore, no poor metabolizers (95% C.I.: 0.1%, 5.2%) were detected in the population sample studied.
摘要
- 在89名无亲缘关系的库纳美洲印第安受试者中研究了去甲丙咪嗪（DB）的代谢氧化情况。2. 完整药物及其4-羟基代谢物（4-HD）的尿回收率的均值和标准差分别为：%DB：6.8±4.5；%4-HD：16.0±9.1；%总和：22.8±12.0。DB的log10代谢比（LMRDB）分布在一个单一模式内，偏度不显著（-0.01，P>0.10），该模式为单峰（对数核密度和最大似然法）且呈正态分布（χ2 = 22.5；自由度 = 15；P>0.09；检验效能>80%）。3. 因此，在所研究的人群样本中未检测到慢代谢者（95%置信区间：0.1%，5.2%）。
相似文献
1
Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama.巴拿马库纳美洲印第安人中异喹胍代谢率的单峰分布。
Br J Clin Pharmacol. 1990 Aug;30(2):281-5. doi: 10.1111/j.1365-2125.1990.tb03776.x.
2
The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers.巴拿马库纳美洲印第安人中司巴丁的氧化代谢：缺乏代谢缺陷者的证据
Clin Pharmacol Ther. 1988 Apr;43(4):456-65. doi: 10.1038/clpt.1988.58.
3
An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá.关于异喹胍和鹰爪豆碱代谢模式种族独特性的观察：对巴拿马恩加韦瓜伊米美洲印第安人的一项研究。
Br J Clin Pharmacol. 1989 Oct;28(4):493-4. doi: 10.1111/j.1365-2125.1989.tb03532.x.
4
[Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].
Yao Xue Xue Bao. 1991;26(4):250-4.
5
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.芬兰人群中的异喹胍氧化：口服避孕药对代谢率的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x.
6
7
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
8
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Genet Epidemiol. 1989;6(4):517-24. doi: 10.1002/gepi.1370060406.
9
Polymorphic debrisoquin metabolism in a Turkish population.土耳其人群中异喹胍代谢的多态性
Clin Pharmacol Ther. 1994 Apr;55(4):399-401. doi: 10.1038/clpt.1994.48.
10
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.中国本土人群与瑞典人群在异喹胍和S-美芬妥因多态性羟化方面存在显著差异。
Clin Pharmacol Ther. 1992 Apr;51(4):388-97. doi: 10.1038/clpt.1992.38.
引用本文的文献
1
Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.中美洲和加勒比地区的药物遗传学研究活动：一项系统综述。
Pharmacogenomics. 2016 Oct;17(15):1707-1724. doi: 10.2217/pgs-2016-0053. Epub 2016 Sep 16.
本文引用的文献
1
Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.
Can J Physiol Pharmacol. 1980 Sep;58(9):1142-4. doi: 10.1139/y80-173.
2
Pharmacoanthropology: drug metabolism.药物人类学：药物代谢
Fed Proc. 1984 May 15;43(8):2326-31.
3
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.日本人群与白种人群之间在异喹胍和甲妥英羟基化遗传多态性上的种族差异。
Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194.
4
A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway.关于斯巴丁在恩加韦·瓜伊米美洲印第安人中的瞬时多态性氧化的初步说明：一个具有该途径暂定系统发育时间框架的遗传分化案例。
Clin Pharmacol Ther. 1988 Sep;44(3):343-52. doi: 10.1038/clpt.1988.160.
5
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Hum Toxicol. 1988 May;7(3):273-6. doi: 10.1177/096032718800700308.
6
The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers.巴拿马库纳美洲印第安人中司巴丁的氧化代谢：缺乏代谢缺陷者的证据
Clin Pharmacol Ther. 1988 Apr;43(4):456-65. doi: 10.1038/clpt.1988.58.
7
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
Clin Pharmacol Ther. 1988 Oct;44(4):431-5. doi: 10.1038/clpt.1988.176.
8
Low frequency of slow debrisoquine hydroxylation in a native Chinese population.中国本土人群中慢代谢异喹胍羟化反应的低发生率。
Lancet. 1987 Oct 10;2(8563):852-3. doi: 10.1016/s0140-6736(87)91034-8.
9
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.检测提示药物代谢多态性的数据频率分布中的双峰性——直方图和概率单位图。
Br J Clin Pharmacol. 1989 Dec;28(6):647-53. doi: 10.1111/j.1365-2125.1989.tb03557.x.
10
An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá.关于异喹胍和鹰爪豆碱代谢模式种族独特性的观察：对巴拿马恩加韦瓜伊米美洲印第安人的一项研究。
Br J Clin Pharmacol. 1989 Oct;28(4):493-4. doi: 10.1111/j.1365-2125.1989.tb03532.x.
Zotero 插件